Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1262-8. doi: 10.1016/j.ijrobp.2012.10.004. Epub 2012 Nov 20.
To characterize the rates of acute and late duodenal and other gastrointestinal (GI) toxicities among patients treated for cervical and endometrial cancers with extended-field intensity modulated radiation therapy (EF-IMRT) to the paraaortic nodes and to analyze dose-volume relationships of GI toxicities.
Fifty-three patients with endometrial or cervical cancer underwent EF-IMRT to the paraaortic nodes, of whom 46 met the inclusion criteria for GI toxicity and 45 for duodenal toxicity analysis. The median prescribed dose to the paraaortic nodes was 54 Gy (range, 41.4-65 Gy). The 4 duodenal segments, whole duodenum, small bowel loops, peritoneum, and peritoneum plus retroperitoneal segments of colon were contoured retrospectively, and dosimetric analysis was performed to identify dose-volume relationships to grade ≥3 acute (<90 day) and late (≥90 day) GI toxicity.
Only 3/46 patients (6.5%) experienced acute grade ≥3 GI toxicity and 3/46 patients (6.5%) experienced late grade ≥3 GI toxicity. The median dose administered to these 6 patients was 50.4 Gy. One of 12 patients who received 63 to 65 Gy at the level of the renal hilum experienced grade 3 GI toxicity. Dosimetric analysis of patients with and without toxicity revealed no differences between the mean absolute or fractional volumes at any 5-Gy interval between 5 Gy and the maximum dose. None of the patients experienced duodenal toxicity.
Treatment of paraaortic nodes with IMRT is associated with low rates of GI toxicities and no duodenal-specific toxicity, including patients treated with concurrent chemotherapy. This technique may allow sufficient dose sparing of the bowel to enable safe dose escalation to at least 65 Gy.
描述接受扩大野调强放疗(EF-IMRT)治疗的宫颈癌和子宫内膜癌患者的急性和晚期十二指肠及其他胃肠道(GI)毒性的发生率,并分析 GI 毒性的剂量-体积关系。
53 例子宫内膜癌或宫颈癌患者接受了扩大野调强放疗(EF-IMRT)治疗,其中 46 例符合 GI 毒性纳入标准,45 例符合十二指肠毒性分析纳入标准。主动脉旁淋巴结的中位处方剂量为 54 Gy(范围,41.4-65 Gy)。回顾性勾画 4 个十二指肠段、整个十二指肠、小肠袢、腹膜和腹膜加结肠后腹膜段,并进行剂量学分析,以确定≥3 级急性(<90 天)和晚期(≥90 天)GI 毒性的剂量-体积关系。
仅有 3/46 例(6.5%)患者出现急性≥3 级 GI 毒性,3/46 例(6.5%)患者出现晚期≥3 级 GI 毒性。这 6 例患者接受的中位剂量为 50.4 Gy。12 例肾门水平接受 63-65 Gy 剂量的患者中,有 1 例发生 3 级 GI 毒性。有/无毒性的患者之间,在 5 Gy 至最大剂量之间的任何 5 Gy 间隔内,平均绝对或分数体积均无差异。没有患者发生十二指肠毒性。
IMRT 治疗主动脉旁淋巴结与较低的 GI 毒性发生率相关,且无特定于十二指肠的毒性,包括接受同期化疗的患者。该技术可能允许对肠道进行足够的剂量保护,从而能够安全地将剂量提高至至少 65 Gy。